Table 4.
Comparison between the screening methods; SarSA-Mod, SARC-F, SARCF-Calf (31 cm), and SARCF-Calf (33/34 cm).
| Area under Curve | Sensitivity (%) | Specificity (%) | Positive predictive value (%) | Negative predictive value (%) | |
|---|---|---|---|---|---|
| SARC-F | |||||
| Men | 0.42 (0.37–0.47) | 13.8 (9.8–18.8) | 95.9 (94.3–97.1) | 50.0 (37.6–62.4) | 78.9 (76.2–81.4) |
| Women | 0.45 (0.41–0.49) | 29.6 (24.1–35.6) | 73.4 (70.3–76.4) | 25.3 (20.4–30.6) | 77.6 (74.4–80.3) |
| Total | 0.57 (0.54–0.60) | 21.9 (18.3–25.7) | 84.5 (82.7–86.2) | 29.0 (25.2–34.8) | 78.2 (76.3–80.1) |
| SARCF-Calf (31 cm) | |||||
| Men | 0.49 (0.43–0.54) | 9.4 (6.0–13.7) | 98.7 (97.6–99.3) | 67.7 (49.5–82.6) | 78.5 (75.9–81.0) |
| Women | 0.62 (0.57–0.66) | 28.4 (23.0–34.3) | 96.1 (94.6–97.3) | 68.7 (59.1–77.5) | 81.6 (79.0–83.9) |
| Total | 0.64 (0.62–0.67) | 19.1 (15.7–22.8) | 97.4 (96.5–98.1) | 68.6 (60.2–76.1) | 80.0 (78.2–81.7) |
| SARCF-Calf (33/34 cm) | |||||
| Men | 0.61 (0.56–0.66) | 27.2 (21.8–33.3) | 92.9 (90.9–94.5) | 53.2 (44.1–62.1) | 81.1 (78.4–83.5) |
| Women | 0.73 (0.69–0.77) | 48.6 (42.4–54.9) | 89.6 (87.4–91.6) | 58.7 (51.8–65.4) | 85.2 (82.7–87.5) |
| Total | 0.73 (0.70–0.76) | 38.2 (33.9–42.6) | 91.2 (89.8–92.5) | 56.6 (51.2–62.0) | 83.1 (81.3–84.8) |
| SarSA-Mod | |||||
| Men | 0.83 (0.80–0.86) | 86.2 (81.3–90.3) | 64.3 (60.9–67.5) | 41.8 (37.5–46.2) | 94.0 (91.7–95.8) |
| Women | 0.88 (0.86–0.90) | 86.1 (81.2–90.0) | 76.5 (73.5–79.3) | 52.6 (47.7–57.5) | 94.8 (92.8–96.3) |
| Total | 0.86 (0.84–0.88) | 86.1 (82.8–89.0) | 70.5 (68.2–72.6) | 46.7 (43.4–49.9) | 94.4 (93.0–95.6) |
SarSA-Mod, Sarcopenia Scoring Assessment Model.